CD155 on Tumor Cells Drives Resistance to Immunotherapy by Inducing the Degradation of the Activating Receptor CD226 in CD8+ T CellsMatthias Braun, Tobias Bald, Indrajit Das et al.|Immunity|2020Cited by 181
Tumor CD155 Expression Is Associated with Resistance to Anti-PD1 Immunotherapy in Metastatic MelanomaAilin Lepletier, Mark J. Smyth, Jason Madore et al.|Clinical Cancer Research|2020Cited by 113
Tumor CD155 Drives Resistance to Immunotherapy by Downregulating the Activating Receptor CD226 in CD8 <sup>+</sup> T CellsMatthias Braun, Tobias Bald, Indrajit Das et al.|SSRN Electronic Journal|2019Cited by 3